China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech. The collaboration aims to establish an antibody drug conjugate (ADC) platform that offers a range of diversified antibodies, highly active small molecule payloads, and linker technology. The platform is designed to provide ADC pharmaceutical customers with more advantageous technological options and efficient, high-quality one-stop ADC CDMO services spanning from research and development to production.
The partnership will focus on several key areas:
① Complementary strategic cooperation in the ADC field, with Apeloa contributing highly active small molecules and ZhenGe offering protein and ADC conjugation services,
② Capitalizing on Apeloa’s strengths in microbial fermentation and advanced biological cell culture for cooperation in synthetic biology,
③ Utilizing the partners’ domestic and international client resources for business development (BD) cooperation in China, Europe, and the United States,
④ Sharing domestic and international market resources for marketing (MKT) cooperation, including joint exhibition booth displays, conference presentations, and various salon activities. Financial details of the agreement were not disclosed.- Flcube.com
